According to TipRanks, Smith is an analyst with an average return of -13.3% and a 33.17% success rate. Smith covers the Healthcare sector, focusing on stocks such as Prometheus Biosciences, Celldex, and MannKind.
Celldex has an analyst consensus of Strong Buy, with a price target consensus of $65.50, which is a 74.81% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $73.00 price target.
Based on Celldex’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $174 thousand and a GAAP net loss of $23.05 million. In comparison, last year the company earned revenue of $685 thousand and had a GAAP net loss of $16.54 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Read More on CLDX:
- RBC Capital Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)
- Intra-Cellular Therapies (ITCI) Gets a Buy from Needham
- Global Blood Therapeutics (GBT) was downgraded to a Hold Rating at SVB Securities
- SVB Securities Sticks to Their Buy Rating for PureTech Health (PRTC)
- Constellation Energy Corporation (CEG) Receives a Buy from Wells Fargo